^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TmEGFR/IL13Rα2 01 CAR-T

    i
    Associations
    News

    Trials

    Company:
    Gilead, University of Pennsylvania
    Drug class:
    EGFR-targeted CAR-T immunotherapy, IL-13-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM (NCT05168423)
    Phase 1
    University of Pennsylvania
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    02/24/2023
    Primary completion :
    12/19/2024
    Completion :
    12/19/2039
    EGFR
    |
    EGFR amplification • EGFR wild-type • IDH wild-type
    |
    cyclophosphamide • fludarabine IV • TmEGFR/IL13Rα2 01 CAR-T